An information processing view of framing effects: The role of causal schemas in decision making

Jerwen Jou,J. Shanteau,R. Harris

DOI: https://doi.org/10.3758/BF03197268

Memory & Cognition

Abstract:

What problem does this paper attempt to address?

Exploring the Role of Artificial Intelligence and Machine Learning in Pharmaceutical Formulation Design

Hrithik Dey,Nisha Arya,Harshita Mathur,Neel Chatterjee,Ruchi Jadon

DOI: https://doi.org/10.61554/ijnrph.v2i1.2024.67

2024-06-30

Abstract:The integration of Artificial Intelligence (AI) and Machine Learning (ML) into pharmaceutical formulation design has brought about a significant transformation, opening up new avenues for innovation and operational efficiency. This review paper aims to extensively examine the utilization of AI and ML in pharmaceutical formulation development, consolidating recent empirical findings and emerging patterns. Meta-analyses examining AI-driven drug discovery and formulation design efforts have revealed promising outcomes, including the acceleration of drug development timelines and enhancements in success rates across preclinical and clinical trials. Notably, a meta-analysis featured in Nature Reviews Drug Discovery sheds light on the pivotal role of AI in rational drug design, resulting in the identification of novel therapeutic candidates boasting improved efficacy and diminished side effects. Furthermore, AI and ML techniques are increasingly being deployed to optimize drug delivery systems, with studies showcasing their effectiveness in devising controlled-release formulations and nano-scale delivery platforms. For instance, the research highlighted in Advanced Drug Delivery Reviews demonstrates the application of ML algorithms in predicting the physicochemical attributes of nanoparticles, thereby aiding in the development of more durable and efficient drug carriers. Despite these advancements, challenges persist, including data scarcity, regulatory complexities, and ethical considerations. Nevertheless, ongoing endeavors to tackle these obstacles coupled with the continual evolution of AI and ML technologies offer promising prospects for the future of pharmaceutical formulation design. In conclusion, this review underscores the transformative influence of AI and ML on pharmaceutical formulation development, underscoring the necessity for sustained research and collaboration to fully leverage these technologies in enhancing healthcare outcomes.
Revolutionizing Drug Formulation: Harnessing Artificial Intelligence and Machine Learning for Enhanced Stability, Formulation Optimization, and Accelerated Development

Appalaraju Dangeti,Deekshi Gladiola Bynagari,Krishnaveni Vydani

DOI: https://doi.org/10.47760/ijpsm.2023.v08i08.003

2023-08-30

International Journal of Pharmaceutical Sciences and Medicine

Abstract:The integration of Artificial Intelligence (AI) and Machine Learning (ML) in the field of pharmaceutical drug formulation has sparked a paradigm shift in the way drug stability is predicted, formulations are optimized, and drug development is expedited. This review delves into the transformative impact of AI and ML techniques on pharmaceutical research and development. It highlights how predictive models driven by AI algorithms are effectively simulating drug degradation pathways and stability profiles, enabling scientists to make informed decisions during formulation design. Moreover, the utilization of ML algorithms to analyze vast datasets has led to the discovery of optimal formulations by identifying critical relationships between formulation variables, excipients, and drug properties. This approach not only reduces experimentation time and costs but also enhances the likelihood of developing robust and effective drug products. Furthermore, AI-powered drug development platforms are shortening the timeline for candidate selection, preclinical evaluations, and clinical trials, thereby accelerating the entire drug development process. This article explores the evolving landscape of AI and ML in drug formulation, discusses challenges, and anticipates future prospects in this transformative field.
A Comprehensive Review on Machine Learning and Deep Learning Methods in Drug Discovery

Sneha Khaire,Pawan Bhaladhare

DOI: https://doi.org/10.17762/ijritcc.v10i10.5728

2022-10-31

International Journal on Recent and Innovation Trends in Computing and Communication

Abstract:Due to its ability to drastically cut the time and money required to develop new medicines, artificial intelligence (AI) based drug discovery has recently attracted a lot of attention. The fields of drug research and development have made use of machine learning (ML) and deep learning (DL) technologies to develop new medication prospects. Machine learning and deep learning-based techniques are emerging at every level of the drug development process as a result of the proliferation of drug-related data. Preclinical testing of a target of interest has proven to be particularly tough for pharmaceutical chemists, who face significant challenges in selecting and developing effective drugs. Machine learning and deep learning algorithms are now extensively used in approaches for generating therapeutic targets and innovative medication development in order to increase the accuracy, efficiency, and quality of created outputs. This review focuses on the application of machine learning and deep learning algorithms in drug development, as well as related approaches. We'll look at the approaches and methods that seem most promising in terms of their potential impact.
Application of Machine Learning in Drug Discovery and Development Lifecycle

Geerisha Jain

DOI: https://doi.org/10.22161/ijmpd.6.6.4

2022-01-01

Abstract:Machine learning and Artificial Intelligence have significantly advanced in recent years owing to their potential to considerably increase the quality of life while reducing human workload. The paper demonstrates how AI and ML are used in the drug development process to shorten and enhance the overall timeline. It contains pertinent information on a variety of Machine Learning approaches and algorithms that are used across the whole drug development process to speed up research, save expenses, and reduce risks related to clinical trials. A range of QSAR analysis, hit finding, and de novo drug design applications are used in the pharmaceutical industry to enhance decision-making. As technologies like high-throughput screening and computation analysis of databases used for lead and target identification and development create and integrate vast volumes of data, machine learning and deep learning have grown in importance. It has also been emphasized how these cognitive models and tools may be used in lead creation, optimization, and thorough virtual screening. In this paper, problem statements and the corresponding state-of-the-art models have been considered for target validation, prognostic biomarkers, and digital pathology. Machine Learning models play a vital role in the various operations related to clinical trials embracing protocol optimization, participant management, data analysis and storage, clinical trial data verification, and surveillance. Post-development drug monitoring and unique industrially prevalent ML applications of pharmacovigilance have also been discussed. As a result, the goal of this study is to investigate the machine learning and deep learning algorithms utilised across the drug development lifecycle as well as the supporting techniques that have the potential to be useful.
Applications of machine learning in drug discovery and development

Jessica Vamathevan,Dominic Clark,Paul Czodrowski,Ian Dunham,Edgardo Ferran,George Lee,Bin Li,Anant Madabhushi,Parantu Shah,Michaela Spitzer,Shanrong Zhao

DOI: https://doi.org/10.1038/s41573-019-0024-5

IF: 112.288

2019-04-11

Nature Reviews Drug Discovery

Abstract:Drug discovery and development pipelines are long, complex and depend on numerous factors. Machine learning (ML) approaches provide a set of tools that can improve discovery and decision making for well-specified questions with abundant, high-quality data. Opportunities to apply ML occur in all stages of drug discovery. Examples include target validation, identification of prognostic biomarkers and analysis of digital pathology data in clinical trials. Applications have ranged in context and methodology, with some approaches yielding accurate predictions and insights. The challenges of applying ML lie primarily with the lack of interpretability and repeatability of ML-generated results, which may limit their application. In all areas, systematic and comprehensive high-dimensional data still need to be generated. With ongoing efforts to tackle these issues, as well as increasing awareness of the factors needed to validate ML approaches, the application of ML can promote data-driven decision making and has the potential to speed up the process and reduce failure rates in drug discovery and development.

pharmacology & pharmacy,biotechnology & applied microbiology
Machine Learning Approaches and their Applications in Drug Discovery and Design

Sonal Priya,Garima Tripathi,Dev Bukhsh Singh,Priyanka Jain,Abhijeet Kumar

DOI: https://doi.org/10.1111/cbdd.14057

2022-04-15

Abstract:Machine learning approaches are used in various areas of Chemoinformatics such as reaction representation, de novo designing, structure determination, descriptor analysis, chemometrics, etc.This review is focused on several machine learning approaches used in chemoinformatics. Machine learning approaches provide tools and algorithms to improve drug discovery. Many physicochemical properties of drugs like toxicity, absorption, drug‐drug interaction, carcinogenesis, and distribution have been effectively modeled by QSAR techniques. Machine learning is a subset of artificial intelligence and this technique has shown tremendous potential in the field of drug discovery. Techniques discussed in this review are capable of modeling non‐linear datasets, as well as big data of increasing depth and complexity. Various machine learning‐based approaches are being used for drug target prediction, modeling the structure of drug target, binding site prediction, ligand‐based similarity searching, de novo designing of ligands with desired properties, developing scoring functions for molecular docking, building QSAR model for biological activity prediction, and prediction of pharmacokinetic and pharmacodynamic properties of ligands. In recent years, these predictive tools and models have achieved good accuracy. By the use of more related input data, relevant parameters, and appropriate algorithms, the accuracy of these predictions can be further improved.

biochemistry & molecular biology,chemistry, medicinal
Machine Learning Applications in Drug Discovery

T V Geetha,S Sendhilkumar

DOI: https://doi.org/10.26434/chemrxiv-2024-1zwr6-v2

2024-09-26

Abstract:Integrating machine learning (ML) into drug discovery has ushered in a new era of innovation, dramatically enhancing the efficiency and precision of identifying and developing new therapeutics. This review provides a comprehensive analysis of the current applications of machine learning in drug discovery, focusing on its transformative impact across various stages of the drug development pipeline. We delve into key ML methodologies, including supervised and unsupervised learning, neural networks, and reinforcement learning, examining their underlying principles and specific contributions to drug discovery processes. By exploring case studies and recent advancements, this review illustrates how ML algorithms have been utilized to predict drug-target interactions, optimize drug design, and streamline clinical trial processes. Furthermore, we discuss the challenges and limitations of implementing ML techniques in this field and highlight emerging trends and future directions. This review aims to offer researchers a thorough understanding of ML's potential to revolutionize drug discovery and equip them with the insights needed to leverage these technologies effectively.

Chemistry
Machine learning in drug delivery

Adam J Gormley

DOI: https://doi.org/10.1016/j.jconrel.2024.06.045

Abstract:For decades, drug delivery scientists have been performing trial-and-error experimentation to manually sample parameter spaces and optimize release profiles through rational design. To enable this approach, scientists spend much of their career learning nuanced drug-material interactions that drive system behavior. In relatively simple systems, rational design criteria allow us to fine tune release profiles and enable efficacious therapies. However, as materials and drugs become increasingly sophisticated and their interactions have non-linear and compounding effects, the field is suffering the Curse of Dimensionality which prevents us from comprehending complex structure-function relationships. In the past, we have embraced this complexity by implementing high-throughput screens to increase the probability of finding ideal compositions. However, this brute force method was inefficient and led many to abandon these fishing expeditions. Fortunately, methods in data science including artificial intelligence / machine learning (AI/ML) are providing ideal analytical tools to model this complex data and ascertain quantitative structure-function relationships. In this Oration, I speak to the potential value of data science in drug delivery with particular focus on polymeric delivery systems. Here, I do not suggest that AI/ML will simply replace mechanistic understanding of complex systems. Rather, I propose that AI/ML should be yet another useful tool in the lab to navigate complex parameter spaces. The recent hype around AI/ML is breathtaking and potentially over inflated, but the value of these methods is poised to revolutionize how we perform science. Therefore, I encourage readers to consider adopting these skills and applying data science methods to their own problems. If done successfully, I believe we will all realize a paradigm shift in our approach to drug delivery.
Application of Artificial Intelligence and Machine Learning in Drug Discovery and Development

Madhukiran Parvathaneni,Abduselam K. Awol,Monika Kumari,Ke Lan,Manisha Lingam

DOI: https://doi.org/10.22270/jddt.v13i1.5867

2023-01-15

Journal of Drug Delivery and Therapeutics

Abstract:Drug discovery has traditionally been a time consuming and expensive endeavor. Additionally, drugs weren’t as effectively designed as those that are being predicted and developed through AI and ML today. Machine learning is a form of artificial intelligence that develops and evolves based on experience (similarly to the human mind), and is more recently being utilized in drug discovery and design. The integration of AI and ML into the drug discovery and development process has allowed for higher target precision, lower toxicity, and better dosage formulations. AI more generally has been introduced to and has been leveraged at, each step of drug development, including target identification and validation, hit identification, as well as hit to lead optimization, and has been key in shortening the previously lengthy drug screening process. AI and ML has also been applied downstream in drug formulation where it has maximized resource utilization and is allowing for web-based 3D printing of drugs. Application of AI in the drug development process has also been extended to the modeling of novel drug-like compounds to predict their ADMET properties. This review will address the stages of drug discovery and development in which the application of AI and ML modeling has altered the traditional development of drugs. Keywords: Drug discovery, machine learning, artificial intelligence, computational drug development.
Revolutionizing Pharmaceutical Research: Harnessing Machine Learning for a Paradigm Shift in Drug Discovery

Ali Husnain,Saad Rasool,Ayesha Saeed,Hafiz Khawar Hussain

DOI: https://doi.org/10.47709/ijmdsa.v2i2.2897

2023-09-27

Abstract:The fusion of machine learning (ML) and artificial intelligence (AI) is experiencing a dramatic transition in the field of pharmaceutical research and development. This study examines the several effects of machine learning (ML) on different phases of medication discovery, development, and patient care. The capability of ML to quickly process huge chemical libraries and forecast interactions with target proteins is studied, starting with compound screening and selection. The potential for fewer false positives and negatives, improved hit prediction accuracy, and ensemble technique use are underlined. The part that machine learning plays in enhancing Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profile is then explained. ML models anticipate compound actions inside the human body by analyzing molecular structures and characteristics, improving assessments of drug safety and efficacy. The article goes into further detail about predictive modeling, highlighting how machine learning may be used to find prospective therapeutic targets and confirm their applicability. The combination of multi-omics data, deep learning, and the possibility to identify similar molecular pathways across diseases highlight the game-changing potential of machine learning in this field. The article also covers the use of ML in clinical trials, highlighting its benefits for trial planning, patient recruitment, real-time monitoring, and individualized therapy predictions. By utilizing computational analysis and quantum physics, the power of machine learning-driven de novo drug creation is examined, revealing the potential to develop new therapeutic candidates. In this article, the ethical issues surrounding AI-driven drug discovery are discussed, with a focus on the necessity of transparent data utilization, human oversight, and responsible data consumption. The report ends by predicting ML's potential for pharmaceutical R&D in the future. Accelerated drug discovery pipelines, the rise of customized medicine powered by predictive models, optimized clinical trials, and a change in medication repurposing tactics are all envisaged in this. The report emphasizes the revolutionary potential of ML in altering pharmaceutical research and development while noting obstacles in data quality, model interpretability, ethics, and interdisciplinary collaboration. It is suggested that the ethical integration of AI technologies, interdisciplinary cooperation, and regulatory modifications are essential steps to unlock the full potential of ML and AI and, ultimately, provide patients throughout the world with safer, more efficient, and individualized treatments.
Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development

Chayna Sarkar,Biswadeep Das,Vikram Singh Rawat,Julie Birdie Wahlang,Arvind Nongpiur,Iadarilang Tiewsoh,Nari M Lyngdoh,Debasmita Das,Manjunath Bidarolli,Hannah Theresa Sony

DOI: https://doi.org/10.3390/ijms24032026

2023-01-19

Abstract:The discovery and advances of medicines may be considered as the ultimate relevant translational science effort that adds to human invulnerability and happiness. But advancing a fresh medication is a quite convoluted, costly, and protracted operation, normally costing USD ~2.6 billion and consuming a mean time span of 12 years. Methods to cut back expenditure and hasten new drug discovery have prompted an arduous and compelling brainstorming exercise in the pharmaceutical industry. The engagement of Artificial Intelligence (AI), including the deep-learning (DL) component in particular, has been facilitated by the employment of classified big data, in concert with strikingly reinforced computing prowess and cloud storage, across all fields. AI has energized computer-facilitated drug discovery. An unrestricted espousing of machine learning (ML), especially DL, in many scientific specialties, and the technological refinements in computing hardware and software, in concert with various aspects of the problem, sustain this progress. ML algorithms have been extensively engaged for computer-facilitated drug discovery. DL methods, such as artificial neural networks (ANNs) comprising multiple buried processing layers, have of late seen a resurgence due to their capability to power automatic attribute elicitations from the input data, coupled with their ability to obtain nonlinear input-output pertinencies. Such features of DL methods augment classical ML techniques which bank on human-contrived molecular descriptors. A major part of the early reluctance concerning utility of AI in pharmaceutical discovery has begun to melt, thereby advancing medicinal chemistry. AI, along with modern experimental technical knowledge, is anticipated to invigorate the quest for new and improved pharmaceuticals in an expeditious, economical, and increasingly compelling manner. DL-facilitated methods have just initiated kickstarting for some integral issues in drug discovery. Many technological advances, such as "message-passing paradigms", "spatial-symmetry-preserving networks", "hybrid de novo design", and other ingenious ML exemplars, will definitely come to be pervasively widespread and help dissect many of the biggest, and most intriguing inquiries. Open data allocation and model augmentation will exert a decisive hold during the progress of drug discovery employing AI. This review will address the impending utilizations of AI to refine and bolster the drug discovery operation.
A review on artificial intelligence and machine learning used in pharmaceutical research

Utkarsha A. Wadighare,Swati P. Deshmukh

DOI: https://doi.org/10.30574/gscbps.2024.26.1.0446

2024-01-30

GSC Biological and Pharmaceutical Sciences

Abstract:The cutting-edge upward push of artificial intelligence and system mastering has been of considerable size. It has reduced the human workload move forward exceptional of life exceptionally. This article describes using artificial intelligence and system learning to augment drug discovery and upgrade to lead them to more well organised and correct. In medication, specialties in which images are vitally important, like radiology, pathology or oncology, have seized the able to be done and full-size efforts in studies and development were deployed to switch the adaptness of AI to scientific packages. With AI becoming a extra widespread device for usual scientific imaging evaluation duties, together with prognosis, segmentation, or classification, the important thing for a secure and efficient use of medical AI packages. This body of work supported the jobs of system gaining knowledge of and synthetic intelligence in facilitating drug expansion and finding out methods, making them greater cost-powerful or altogether casting off the want for clinical trials, as a result of the potential to conduct simulations the usage of those technologies. Doing so will assist in separating wish from hype and lead to knowledgeable choice making at the top-quality use of AI/ML in drug development. Machine studying strategies can subterfuge complicated analyzes with huge, heterogeneous, and excessive dimensional information collections without a guide enter, which has proved helpful inside the writing commercial enterprise applications. Combining system mastering, particularly deep getting to know, with human skill and revel in is probably the great manner to coordinate numerous significant facts stores. The magnificent facts-mining capacity of AI innovation has given new essentiality to computer supported medication plans that incorporate more than one clinical concerns are higher than piecemeal data.
A Systematic Literature Review of the Current Status and Future Prospects of Machine Learning Methods and Techniques Applied to Novel Drug Discovery

Ali Abdelkrim,Abdelkrim Bouramoul,Imene Zenbout

DOI: https://doi.org/10.4018/ijoci.312223

2022-10-21

International Journal of Organizational and Collective Intelligence

Abstract:Drug development is the hardest phase for the pharmaceutical industry because it is extremely costly and time consuming. Though, due to the growing demand to produce safe and innovative medicines faster and more cost-effectively, the scientific community changed its objective into enhancing the lead identification and the lead optimization at the early discovery phase. This could be achieved using recent intelligent technologies that allow virtual screening as well as quantitative structure-activity relationship (QSAR) modeling to define the possible relationships between chemical compounds and biological activities. Among recent technologies, artificial intelligence (AI) has been introduced as a powerful solution to address problems related to drug discovery and development. In particular, machine learning (ML) has been meaningfully instrumental in the production of new drug candidates. In this work, we review the fundamental principles of machine learning algorithms, study and discuss their application and current issues in drug development.
What are the current challenges for machine learning in drug discovery and repurposing?

Tero Aittokallio

DOI: https://doi.org/10.1080/17460441.2022.2050694

2022-03-08

Expert Opinion on Drug Discovery

Abstract:Machine learning (ML) approaches have been increasingly adopted for computer-assisted drug discovery in the recent years. This rapid progress is mostly due to the large-scale data sets available for ML model training, along with the development of deep learning (DL) and other artificial intelligence (AI) approaches that enable an integrated use of heterogeneous compound and target data, ranging from chemical structure to biochemical, in vitro, in vivo, and clinical endpoints for treatment response modeling. Exciting opportunities to apply ML and AI methods occur in all stages of drug discovery and development, including target identification and validation, prediction of molecular structure and function, and compound screening and optimization [1]. Based on high-quality training data, supervised learning and feature selection offers a systematic means for identification of predictive biomarkers for precision medicine; for instance, using clinical data, such predictive approaches may provide real-word evidence of treatment responses for designing marker-based trials and improving patient selection. In particular, cancer research and precision oncology has witnessed in the past few years an enormous progress in the application of ML to cancer detection and diagnosis, identification of new targets for anticancer drug discovery and repurposing, along with prediction of treatment outcomes for cancer patients [2].

pharmacology & pharmacy
Exploring the applications of formulation-based drug development strategies in neurological disorders using artificial intelligence and machine learning approaches

Ashok Aspatwar,Ranajit Nath,Ratul Bhowmik,Rajesh Jesudasan

DOI: https://doi.org/10.26434/chemrxiv-2024-21hd2

2024-07-16

Abstract:The study of artificial intelligence (AI), a multidimensional field, empowers machines with the ability to understand, reason, learn, and perform tasks autonomously. As a pivotal branch of computer science, AI excels in analyzing complex medical data and uncovering significant relationships for diverse diagnostic purposes. In neurology, innovative AI techniques have revolutionized diagnostics, management, and outcome prediction, opening new avenues for tackling neurological disorders. AI encompasses two key subsets: machine learning (ML) and deep learning (DL), which have gained immense popularity for predicting bioactivity, toxicology, physical and chemical properties, formulation quality, and drug-target interactions. The complexity of neurological diseases (ND) presents unique challenges in developing treatments for the central nervous system (CNS), given obstacles like the blood-brain barrier and high medication attrition rates. However, AI algorithms, leveraging vast datasets, efficiently analyze, interpret, and predict unknown facts, significantly accelerating CNS drug discovery. Deep learning architectures have furthered our understanding of AI's potential to address complex CNS disease issues, transforming the drug development landscape. This review delves into AI, ML, and their applications in advancing CNS drug and formulation development. It provides comprehensive, up-to-date insights on AI/ML advancements in neurology, emphasizing nanoparticle-based drug delivery systems. Additionally, the review covers ML algorithms' roles in de novo drug design, structure-based drug design, ligand-based drug design, absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction, and drug repurposing. Despite notable progress, significant challenges remain in enhancing AI's practical application in neurology. Overcoming these hurdles requires compiling extensive data and developing interpretable AI systems, paving the way for groundbreaking advancements in CNS drug development.

Chemistry
Machine learning in preclinical drug discovery

Denise B. Catacutan,Jeremie Alexander,Autumn Arnold,Jonathan M. Stokes

DOI: https://doi.org/10.1038/s41589-024-01679-1

IF: 14.8

2024-07-20

Nature Chemical Biology

Abstract:Drug-discovery and drug-development endeavors are laborious, costly and time consuming. These programs can take upward of 12 years and cost US $2.5 billion, with a failure rate of more than 90%. Machine learning (ML) presents an opportunity to improve the drug-discovery process. Indeed, with the growing abundance of public and private large-scale biological and chemical datasets, ML techniques are becoming well positioned as useful tools that can augment the traditional drug-development process. In this Perspective, we discuss the integration of algorithmic methods throughout the preclinical phases of drug discovery. Specifically, we highlight an array of ML-based efforts, across diverse disease areas, to accelerate initial hit discovery, mechanism-of-action (MOA) elucidation and chemical property optimization. With advances in the application of ML across diverse therapeutic areas, we posit that fully ML-integrated drug-discovery pipelines will define the future of drug-development programs.

biochemistry & molecular biology
Transformative Target-Based Approaches

Akshata Yashwant Patne,Sai Madhav Dhulipala,William Lawless,Satya Prakash,Shyam S. Mohapatra,Subhra Mohapatra

DOI: https://doi.org/10.3390/ijms252212233

IF: 5.6

2024-11-18

International Journal of Molecular Sciences

Abstract:The complexities inherent in drug development are multi-faceted and often hamper accuracy, speed and efficiency, thereby limiting success. This review explores how recent developments in machine learning (ML) are significantly impacting target-based drug discovery, particularly in small-molecule approaches. The Simplified Molecular Input Line Entry System (SMILES), which translates a chemical compound's three-dimensional structure into a string of symbols, is now widely used in drug design, mining, and repurposing. Utilizing ML and natural language processing techniques, SMILES has revolutionized lead identification, high-throughput screening and virtual screening. ML models enhance the accuracy of predicting binding affinity and selectivity, reducing the need for extensive experimental screening. Additionally, deep learning, with its strengths in analyzing spatial and sequential data through convolutional neural networks (CNNs) and recurrent neural networks (RNNs), shows promise for virtual screening, target identification, and de novo drug design. Fragment-based approaches also benefit from ML algorithms and techniques like generative adversarial networks (GANs), which predict fragment properties and binding affinities, aiding in hit selection and design optimization. Structure-based drug design, which relies on high-resolution protein structures, leverages ML models for accurate predictions of binding interactions. While challenges such as interpretability and data quality remain, ML's transformative impact accelerates target-based drug discovery, increasing efficiency and innovation. Its potential to deliver new and improved treatments for various diseases is significant.

biochemistry & molecular biology,chemistry, multidisciplinary
Harnessing machine learning potential for personalised drug design and overcoming drug resistance

Mohammed Ageeli Hakami

DOI: https://doi.org/10.1080/1061186x.2024.2365934

2024-06-15

Journal of Drug Targeting

Abstract:Drug resistance in cancer treatment presents a significant challenge, necessitating innovative approaches to improve therapeutic efficacy. Integrating machine learning (ML) in cancer research is promising as ML algorithms outrival in analysing complex datasets, identifying patterns, and predicting treatment outcomes. Leveraging diverse data sources such as genomic profiles, clinical records, and drug response assays, ML uncovers molecular mechanisms of drug resistance, enabling personalised treatment, maximising efficacy and minimising adverse effects. Various ML algorithms contribute to the drug discovery process – Random Forest and Decision Trees predict drug-target interactions and aid in virtual screening, and SVM classify leads on bioactivity data. Neural Networks model QSAR to optimise lead compounds and K-means clustering group compounds with similar chemical properties aiding compound selection. Gaussian Processes predict drug responses, Bayesian Networks infer causal relationships, Autoencoders generate novel compounds, and Genetic Algorithms optimise molecular structures. These algorithms collectively enhance efficiency and success rates in drug design endeavours, from lead identification to optimisation and are cost-effective, empowering clinicians with real-time treatment monitoring and improving patient outcomes. This review highlights the immense potential of ML in revolutionising cancer care through effective drug design to reduce drug resistance, and we have also discussed various limitations and research gaps to understand better.

pharmacology & pharmacy
Re-envisioning the design of nanomedicines: harnessing automation and artificial intelligence

Jonathan Zaslavsky,Pauric Bannigan,Christine Allen

DOI: https://doi.org/10.1080/17425247.2023.2167978

2023-01-23

Expert Opinion on Drug Delivery

Abstract:Interest in nanomedicines has surged in recent years due to the critical role they have played in the COVID-19 pandemic. Nanoformulations can turn promising therapeutic cargo into viable products through improvements in drug safety and efficacy profiles. However, the developmental pathway for such formulations is non-trivial and largely reliant on trial-and-error. Beyond the costly demands on time and resources, this traditional approach may stunt innovation. The emergence of automation, artificial intelligence (AI) and machine learning (ML) tools, which are currently underutilized in pharmaceutical formulation development, offers a promising direction for an improved path in the design of nanomedicines. the potential of harnessing experimental automation and AI/ML to drive innovation in nanomedicine development. The discussion centers on the current challenges in drug formulation research and development, and the major advantages afforded through the application of data-driven methods. The development of integrated workflows based on automated experimentation and AI/ML may accelerate nanomedicine development. A crucial step in achieving this is the generation of high-quality, accessible datasets. Future efforts to make full use of these tools can ultimately contribute to the development of more innovative nanomedicines and improved clinical translation of formulations that rely on advanced drug delivery systems.

pharmacology & pharmacy
Deep Learning in Drug Design—Progress, Methods, and Challenges

Seyyed Saeid Masoomkhah,Khosro Rezaee,Mojtaba Ansari,Hossein Eslami

DOI: https://doi.org/10.18502/fbt.v11i3.15893

2024-06-24

Frontiers in Biomedical Technologies

Abstract:Purpose: Artificial Intelligence (AI), which mimics the human brain structure and operation, simulates intelligence. The aim of Machine Learning (ML), which is a branch of artificial intelligence, is to create models by analyzing data. Another type of artificial intelligence, Deep Learning (DL), depicts geometric changes using several layers of model representations. Since DL broke the computational analysis record, AI has advanced in many areas. Materials and Methods: Contrary to the widespread use of conventional ML methodologies, there is still a need to promote the use and popularity of DL for pharmaceutical research and development. Drug discovery and design have been enhanced by ML and DL in major research projects. To fully realize its potential, drug design must overcome many challenges and issues. Various aspects of medication design must be considered to successfully address these concerns and challenges. This review article explains DL's significance both in technological breakthroughs and in effective medications. Results: There are numerous barriers and substantial challenges associated with drug design associated with DL architectures and key application domains. The article discusses several elements of medication development that have been influenced by existing research. Two widely used and efficient Neural Network (NN) designs are discussed in this article: Convolutional Neural Networks (CNNs) and Recurrent Neural Networks (RNNs). Conclusion: It is described how these tools can be utilized to design and discover small molecules for drug discovery. They are also given an overview of the history of DL approaches, as well as a discussion of some of their drawbacks.

An information processing view of framing effects: The role of causal schemas in decision making

Exploring the Role of Artificial Intelligence and Machine Learning in Pharmaceutical Formulation Design

Revolutionizing Drug Formulation: Harnessing Artificial Intelligence and Machine Learning for Enhanced Stability, Formulation Optimization, and Accelerated Development

A Comprehensive Review on Machine Learning and Deep Learning Methods in Drug Discovery

Application of Machine Learning in Drug Discovery and Development Lifecycle

Applications of machine learning in drug discovery and development

Machine Learning Approaches and their Applications in Drug Discovery and Design

Machine Learning Applications in Drug Discovery

Machine learning in drug delivery

Application of Artificial Intelligence and Machine Learning in Drug Discovery and Development

Revolutionizing Pharmaceutical Research: Harnessing Machine Learning for a Paradigm Shift in Drug Discovery

Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development

A review on artificial intelligence and machine learning used in pharmaceutical research

A Systematic Literature Review of the Current Status and Future Prospects of Machine Learning Methods and Techniques Applied to Novel Drug Discovery

What are the current challenges for machine learning in drug discovery and repurposing?

Exploring the applications of formulation-based drug development strategies in neurological disorders using artificial intelligence and machine learning approaches

Machine learning in preclinical drug discovery

Transformative Target-Based Approaches

Harnessing machine learning potential for personalised drug design and overcoming drug resistance

Re-envisioning the design of nanomedicines: harnessing automation and artificial intelligence

Deep Learning in Drug Design—Progress, Methods, and Challenges